SCHEMBL3020396

SCHEMBL3020396

Cc1cc(C)c(S(=O)(=O)C2CCN(c3nc(-c4ccc(C)c(C)c4)cs3)CC2)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.48
RAB9A P51151 8/20 0.48
NPC1 O15118 7/20 0.48
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPK1 P28482 2/20 0.43
EGFR P00533 3/20 0.42
MEN1 O00255 2/20 0.42
AR P10275 1/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009630 0.92 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3009737 0.90 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3023045 0.89 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3008908 0.89 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3002120 0.89 AR (0.54) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3016731 0.89 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3007528 0.89 MAPT (0.52) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3021488 0.89 MAPK1 (0.47) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3012627 0.88 MAPK1 (0.56) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1
SCHEMBL3018390 0.88 AR (0.44) SMN1; SMN2RAB9ANPC1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.